Cargando…
Clinical utility of the C‐reactive protein:albumin ratio in non‐small cell lung cancer patients treated with nivolumab
BACKGROUND: Nivolumab is a second‐line chemotherapy for non‐small cell lung cancer (NSCLC). This study explored the impact of clinical biomarkers such as neutrophil:lymphocyte ratio (NLR), C‐reactive protein:albumin ratio (CAR), and modified Glasgow prognostic score on the efficacy and outcome of ni...
Autores principales: | Araki, Taisuke, Tateishi, Kazunari, Sonehara, Kei, Hirota, Shuko, Komatsu, Masamichi, Yamamoto, Manabu, Kanda, Shintaro, Kuraishi, Hiroshi, Hanaoka, Masayuki, Koizumi, Tomonobu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919135/ https://www.ncbi.nlm.nih.gov/pubmed/33434414 http://dx.doi.org/10.1111/1759-7714.13788 |
Ejemplares similares
-
Association of lung immune prognostic index with survival outcome in advanced thymic carcinoma patients treated with palliative intent chemotherapy
por: Araki, Taisuke, et al.
Publicado: (2022) -
Predictive value of post‐treatment C‐reactive protein‐to‐albumin ratio in locally advanced non–small cell lung cancer patients receiving durvalumab after chemoradiotherapy
por: Araki, Taisuke, et al.
Publicado: (2022) -
Prognostic value of the geriatric nutritional risk index among patients with previously treated advanced non‐small cell lung cancer who subsequently underwent immunotherapy
por: Sonehara, Kei, et al.
Publicado: (2021) -
The efficacy of amrubicin third‐line chemotherapy in patients with relapsed extensive‐disease small‐cell lung cancer: A retrospective and historical study in a single institute
por: Sonehara, Kei, et al.
Publicado: (2019) -
Predictive Factors Correlated with the Development of Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors
por: Sonehara, Kei, et al.
Publicado: (2022)